






A





B





Supplementary Figure 1. Flow cytometry analysis of HUVEC viability. Panel A: experimental design. Panel B: results from a representative experiment.

A**B**

Supplementary Figure 2. Spike protein expression in HUVEC cultured in the presence of vaccine at different concentrations. Panel A: experimental design. Panel B: results from a representative experiment with 1 µg/ml vaccine. Left: PCR assay; red, 18sRNA (housekeeping gene), green, 4 h; yellow, 24 h; blue, 48 h; pink, 72 h; purple, 144 h. Right: ELISA assay; black circles, calibration curve; white circles: experimental samples.


A**B**

Supplementary Figure 3. IL-6, TNF- α , ICAM-1 and VCAM-1 mRNA levels in HUVEC cultured in the presence of vaccine at different concentrations. Panel A: experimental design. Panel B: results from a representative experiment with 1 µg/ml vaccine. Left: PCR assay; red, 18sRNA (housekeeping gene), green, 4 h; yellow, 24 h; blue, 48 h; pink, 72 h; purple, 144 h. Right: ELISA assay.




Supplementary Figure 4. Effect of vaccine on the adhesion of human leukocytes to HUVEC monolayers, assessed by flow cytometry. Panel A: experimental design. Panel B: results from a representative experiment.

AB Sino Biological
40590-T62



α -actin



Supplementary Figure 5. Complete Western blot of total protein extracts from HUVEC treated for 48 h with the COVID-19 RNA vaccine Spikevax™ at the concentration of 3 μ g/ml. Control: untreated HUVEC.